Physician profile
Rupal S Patel
NPI 1841389665
$17,272.98
in general payments reported to CMS, 2019-2025
34 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $222 · 2021: $812 · 2022: $1,208 · 2023: $9,331 · 2024: $4,375 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,207 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $2,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,206.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $2,795.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,787.27 | 2021-2025 | In.Pact Admiral, Ellipsys Vascular Access System, Turbohawk |
| Horizon Therapeutics Plc | $478.35 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $454.56 | 2019-2024 | Jynarque |
| Bard Peripheral Vascular, INC. | $413.97 | 2019-2023 | Venovo |
| Bayer Healthcare Pharmaceuticals INC. | $258.96 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $193.65 | 2021-2025 | Farxiga, Lokelma |
| Mozarc Medical US LLC | $171.43 | 2023-2025 | Chameleon, Palindrome |
| Novartis Pharmaceuticals Corporation | $159.99 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $125.01 | 2023 | Myfembree |
| Abbvie INC. | $119.71 | 2021 | |
| Sonavex, INC. | $112.00 | 2025 | Echosure, Echomark |
| Vifor Pharma, INC. | $107.78 | 2019-2023 | Veltassa |
| Angiodynamics, INC. | $99.51 | 2022 | |
| Opko Pharmaceuticals, LLC | $75.33 | 2019-2024 | Rayaldee |
| Abbott Laboratories | $68.36 | 2021-2023 | Eterna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.83 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $63.77 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $63.61 | 2019 | |
| Amgen INC. | $49.94 | 2025 | Krystexxa |
| Glaxosmithkline, LLC. | $39.53 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $38.82 | 2020-2025 | Acthar |
| Lilly USA, LLC | $35.78 | 2023-2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $32.28 | 2025 | Empaveli |
| Akebia Therapeutics INC | $28.99 | 2025 | Vafseo |
| Alnylam Pharmaceuticals INC. | $28.52 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.21 | 2025 | Purified Cortrophin Gel |
| Becton, Dickinson and Company | $24.19 | 2025 | Covera |
| Ascendis Pharma Endocrinology INC | $23.35 | 2025 | Yorvipath |
| Renalytix Ai, INC. | $23.30 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Aurinia Pharma U.S., INC. | $22.55 | 2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $21.35 | 2021 | |
| Medtronic Vascular, INC. | $21.24 | 2019 | |
| Scpharmaceuticals INC. | $19.25 | 2025 | |
| Travere Therapeutics, INC. | $18.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.